Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Kristinsson, Sigurður Y.; Goldin, Lynn R.; Björkholm, Magnus; Koshiol, Jill; Turesson, Ingemar; Landgren, Ola

doi:10.3324/haematol.2009.008979

Cited by 31 publications

(27 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The average The risk factors for developing MM are not well defined but there is evidence for involvement of genetic factors because the first-degree relatives of people with MM are at greater risk of developing MM and related conditions than the first-degree relatives of people without MM. 8,18 Epidemiological studies have looked for evidence of a causal link between a range of potential environmental risk factors and MM but, in general, these have not produced consistent results. 4,8 Diagnosis and staging Multiple myeloma is typically diagnosed in secondary care using a combination of tests such as urine tests, blood tests, bone marrow examination, imaging, plain radiograph and/or magnetic resonance imaging.…”

Section: Epidemiologymentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Picot

Cooper²,

Bryant³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address.Paying by credit card You can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume.How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. HTAThe clinical effectiveness and costeffectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation NIHR Health Technology Assessment programmeThe Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clin...

show abstract

Section: Epidemiologymentioning

confidence: 99%

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Picot

Cooper²,

Bryant³

et al. 2011

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…58,59 Chronic antigen stimulation from prior autoimmune, infectious, inflammatory, allergic disorders and immune dysregulation may play a role in pathogenesis of both multiple myeloma and AML/MDS. [60][61][62] Recently, solid organ transplant patients receiving immunosuppressive therapy have been reported to be at risk for the development of AML. 63 In addition, socioeconomic status has been shown to influence survival in both multiple myeloma and AML, suggesting that lifestyle factors in these disorders are of importance.…”

Section: Environmental Factorsmentioning

confidence: 99%

Second malignancies after multiple myeloma: from 1960s to 2010s

Thomas

Mailankody

Korde

et al. 2012

Blood

115

109

View full text Add to dashboard Cite

Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients treated with lenalidomide as maintenance (vs placebo). This fact has prompted concern and highlighted the association between multiple myeloma and second malignancies. Furthermore, an excess of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after multiple myeloma has been known for over 4 decades. Most prior studies have been restricted because of small numbers of patients, inadequate follow-up, and limitations of ascertainment of second malignancies. Although the underlying biologic mechanisms of AML/MDS after multiple myeloma are unknown, treatment-related factors are presumed to be responsible. Recently, an excess risk of AML/MDS was found among 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supporting a role for disease-related factors. Furthermore, there is evidence to suggest that polymorphisms in germline genes may contribute to a person's susceptibility to subsequent cancers, whereas the potential influence of environmental and behavioral factors remains poorly understood. This review discusses current knowledge regarding second malignancies after multiple myeloma and gives future directions for efforts designed to characterize underlying biologic mechanisms, with the goal to maximize survival and minimize the risk for second malignancies for individual patients. (Blood. 2012;119(12): 2731-2737) IntroductionAfter decades of virtually no progress, multiple myeloma survival has improved significantly in the last 10 years, in younger patients even 2-to 3-fold. 1-3 Indeed, multiple myeloma has seen more remarkable progress in treatment and patient outcomes than any other cancer in the last decade. With improvements in survival, a relatively new clinical challenge that has emerged is the risk of second malignancies. This pattern of increase in second malignancies has been observed in other cancers with available curative therapies and favorable outcomes. Survivors of testicular cancer are at up to 3-fold higher risk of developing a second malignancy than the general population. 4 Survivors of Hodgkin lymphoma have more than 3 times greater risk of solid tumors. Fifteen years after diagnosis, the cumulative mortality from second malignancies exceeds cumulative mortality from Hodgkin lymphoma. 5,6 In the United States alone, the number of cancer survivors has tripled since 1971 and is growing by 2% each year; cancer survivors constitute 3.5% of the United States population. 7 Indeed, secondor higher-order cancers account for 18% of incident cancers in the United States, making them the third most common cancer diagnosis. 7 Based on the National Cancer Institute Surveillance, Epidemiology and End Results (NCI SEER) database, compared with the general population, cancer survivors have a 14% increased risk of developing a malignancy. 7 In the late 1960s, based on a restricted number of patients, an association betwee...

show abstract

“…6,19,27 For example, a patient with Waldenström's macroglobulinemia for 37 years 17 had three children with IgM M-spikes and/or hypogammaglobulinemia. As many as 20% of WM patients have a family member with such immunoglobulin abnormalities.…”

Section: Immunoglobulin M Antibodies To Neural Antigensmentioning

confidence: 99%

“…Clinical data support the role of chronic antigenic stimulation, which results in autoantibodies or antibodies to microbial antigens. 26,27 Foreign antigens such as bacterial lipopolysaccharide or hepatitis C virus may play a putative role in these disorders. 28 It has also been suggested that chronic antigenic stimulation may play a role in multiple myeloma.…”

Section: Immunoglobulin M Antibodies To Neural Antigensmentioning

confidence: 99%

Pathophysiology of Waldenstrom's macroglobulinemia

Stone¹,

Pascual²

2010

Haematologica

View full text Add to dashboard Cite

Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies

Abstract: Citation: Kristinsson SY, Goldin LR, Björkholm M, Koshiol J, Turesson I, and Landgren O. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 2009; 94:1581-1589

Cited by 31 publications

References 85 publications

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.

Second malignancies after multiple myeloma: from 1960s to 2010s

Pathophysiology of Waldenstrom's macroglobulinemia

Contact Info

Product

Resources

About